18F-FDG PET/CT in Gastric Cancer (StomachCancer)

April 7, 2026 updated by: Sara Saber Ahmed, Sohag University

Role of 18F-FDG in Gastric Cancer

PET and PET/CT imaging remains promising, and with current and further improvements, PET and PET/CT imaging may make the diagnosis and evaluation of gastric cancer more standardized and accurate.

Study Overview

Status

Completed

Conditions

Detailed Description

This retrospective and prospective study was conducted to evaluate the effectiveness of 18 F-FDG PET/CT imaging in diagnosis of gastric cancer in correlation to other imaging modalities and clinical follow up.

This study included 50 patient pathologically proved gastric cancer. After obtaining written consent from the participants, detailed history was obtained from participants with the help of their data sheets, revision of pathology report (confirmed diagnosis of primary GC), the referral report from the treating physician and any imaging modalities patients were done, FDG PET/CT study was done using dedicated PET/CT scanner, and PET analysis was performed qualitatively and semi qualitatively, tissue biopsy was obtained from patients whenever it was possible.

Results of the current study demonstrate that FDG PET/CT was more accurate and more sensitive than CT in detection of occult distant metastases in advanced or equivocal cases, detection of metabolically active LNs that are morphologically normal on CT, helpful for recurrence detection, and informative for early metabolic response in FDG-avid tumors using standardized criteria (PERCIST),that may not be apparent using other modalities, and may have prognostic value that can change patient management.

PET/CT was more accurate than CT in Detection of Distant metastasis of gastric cancer (liver metastasis, lung metastasis, bone metastasis).

¹⁸F-FDG PET/CT is not a stand-alone staging tool for gastric cancer, but used selectively it meaningfully improves detection of distant metastasis, refines patient selection for radical treatment, and reduces futile surgery.

Clinicians must interpret PET/CT results in light of histologic subtype and complementary diagnostic procedures (endoscopy, laparoscopy, CT). Future work should validate FAPI tracers and define precise clinical pathways where PET/CT adds cost-effective benefit.

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Sohag, Egypt, 82524
        • Sara Saber Ahmed

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The Current Retrospective and Prospective study was conducted among 50 histologically confirmed Gastric Cancer patients ,mean age of the studied cases was 57.58 ± 10.26 years and ranged between (35-77) years. Moreover, the study included 29 males (58%) and 21 females (42%).

Description

Inclusion Criteria:

  1. Patients diagnosed as Gastric Cancer on surgically resected specimens.
  2. Patients with gastric and extragastric metastasis.
  3. Patients with gastric cancer either operated or not

Exclusion Criteria:

  1. Patients with second malignancy (Double primary).
  2. Patient without proven pathology of Cancer Stomach.
  3. Severely ill patient (patient with disturbed conscious level, or couldn't lay supine during the imaging).
  4. Uncontrolled diabetic patient with blood glucose level more than 200mg\dl.
  5. Pregnant women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
diagnosis ,staging ,assessment of treatment response and assessment of recurrence
Time Frame: 12months
assess the value of SUVmax in every detected lesion in relation to the liver uptake and compare if this lesion deteced in other investigation
12months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Collaborators

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 22, 2023

Primary Completion (Actual)

September 22, 2024

Study Completion (Actual)

September 22, 2024

Study Registration Dates

First Submitted

April 7, 2026

First Submitted That Met QC Criteria

April 7, 2026

First Posted (Actual)

April 14, 2026

Study Record Updates

Last Update Posted (Actual)

April 14, 2026

Last Update Submitted That Met QC Criteria

April 7, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • stomach cancer

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

the individual participant data will not be made available to other researchers to maintain patient confidentiality.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe